AIM: We investigated outcomes in patients with advanced non-small-cell lung cancer (NSCLC) and peritoneal involvement.
PATIENTS & METHODS: NSCLC patients with peritoneal carcinomatosis (PC) were included. We evaluated mOS1 (overall survival [OS] from NSCLC diagnosis) and mOS2 (OS from diagnosis of PC).
RESULTS: In total, 60 NSCLC patients were diagnosed with PC, 12 (20%) patients had a diagnosis of NSCLC and synchronous PC with a median OS of 9 months. Smokers had a shorter mOS1 and mOS2 compared with never-smokers; EGFR-mutated patients on tyrosine kinase inhibitors had longer mOS1 and mOS2 than EGFR wild-type patients.
CONCLUSION: Metachronous PC is correlated to a short survival, irrespective of treatment line. Never-smokers and EGFR-mutated patients had improved mOS1 and mOS2 when compared with smokers and EGFR wild-type population.
- Age Factors
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols/pharmacology
- Carcinoma, Non-Small-Cell Lung/drug therapy
- ErbB Receptors/antagonists & inhibitors
- Lung Neoplasms/drug therapy
- Middle Aged
- Non-Smokers/statistics & numerical data
- Peritoneal Neoplasms/drug therapy
- Progression-Free Survival
- Protein Kinase Inhibitors/pharmacology
- Retrospective Studies
- Sex Factors
- Smokers/statistics & numerical data